Modality
ASO
MOA
WEE1i
Target
GLP-1R
Pathway
PD-1/PD-L1
GBM
Development Pipeline
Preclinical
~Aug 2011
→ ~Nov 2012
Phase 1
~Feb 2013
→ ~May 2014
Phase 2
~Aug 2014
→ ~Nov 2015
Phase 3
~Feb 2016
→ ~May 2017
NDA/BLA
Aug 2017
→ Aug 2031
NDA/BLACurrent
NCT04316589
2,847 pts·GBM
2017-08→2030-03·Terminated
NCT07364360
2,042 pts·GBM
2024-06→2031-08·Recruiting
4,889 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-03-254.0y awayPh3 Readout· GBM
2031-08-225.4y awayPh3 Readout· GBM
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Termina…
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2030-03-25 · 4.0y away
GBM
Ph3 Readout
2031-08-22 · 5.4y away
GBM
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04316589 | NDA/BLA | GBM | Terminated | 2847 | HAM-D |
| NCT07364360 | NDA/BLA | GBM | Recruiting | 2042 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 |